Amgen

See the Future at GTC 2024: NVIDIA’s Jensen Huang to Unveil Latest Breakthroughs in Accelerated Computing, Generative AI and Robotics

Retrieved on: 
Tuesday, February 20, 2024
Face, Research, Generative, GTC, Organization, Policy, Telecommunications, Micrometre, SAP Center, Robotics, Student, Head, Health, Transport, Johnson & Johnson, Cohere, HPE, European, ServiceNow, Ecosystem, Cloud computing, Congress, Machine learning, Agriculture, HAI, Biology, Microsoft, JPMorgan Chase, Pixar, DeepMind, Netflix, Amgen, Mistral, Walt Disney Animation Studios, Learning, Physics, Meta, Mercedes-Benz, Foundation models, Dell Technologies, The Walt Disney Company, Knowledge, Goldman Sachs, Snowflake, Boston Dynamics, NVIDIA, Adobe, Second Continental Congress, AI, SAP, Symbiodinium, Polestar 3, Stanford University, Getty Images, Databricks, Deep learning, Volvo, ILM, Medical device

NVIDIA founder and CEO Jensen Huang will deliver the keynote from the SAP Center on Monday, March 18, at 1 p.m. Pacific time.

Key Points: 
  • NVIDIA founder and CEO Jensen Huang will deliver the keynote from the SAP Center on Monday, March 18, at 1 p.m. Pacific time.
  • Since Huang first highlighted machine learning in his 2014 GTC keynote , NVIDIA has been at the forefront of the AI revolution.
  • “Generative AI has moved to center stage as governments, industries and organizations everywhere look to harness its transformative capabilities,” Huang said.
  • From generative AI to robotics to automotive, GTC attendees can interact with dozens of state-of-the-art demos, see the latest autonomous vehicle technology and explore how generative AI will impact virtually every industry.

Global PRMT5 Targeted Therapy Market & Clinical Trials Opportunity Outlook 2024 - ResearchAndMarkets.com

Retrieved on: 
Monday, March 4, 2024
Pharmaceutical, Health, Oncology, Clinical Trials, DNA, Methylation, Viral, Orphan drug, GSK, AMG, FDA, Amgen, Indication, Marketing, Proteolysis, Docetaxel, Cell, Proteolysis targeting chimera, Glioblastoma, Therapy, Cancer, TDP1, Half-life, Survival, PRMT5, Acute myeloid leukemia, Research, Pharmaceutical industry

The "Global PRMT5 Targeted Therapy Market & Clinical Trials Opportunity Outlook 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global PRMT5 Targeted Therapy Market & Clinical Trials Opportunity Outlook 2024" report has been added to ResearchAndMarkets.com's offering.
  • Beyond monotherapies, combination strategies are also being explored in preclinical and clinical trials to enhance PRMT5 inhibition efficacy.
  • However, realizing the full clinical and commercial potential will require validating efficacy and defining suitable patient populations through biomarker-guided trials.
  • Global PRMT5 Targeted Therapy Market & Clinical Trials Opportunity Outlook 2024 Report Highlights:
    PRMT5 Targeted Therapies Clinical Trials by Company, Indication & Phase
    PRMT5 Targeted Therapies in Clinical Trials: >25
    PRMT5 Targeted Therapies Research & Market Trends by Region: US, UK, EU, China & Canada

AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024

Retrieved on: 
Saturday, March 9, 2024
Pustulosis palmaris et plantaris, Psoriasis, CPU socket, Aes, Headache, Diarrhea, Amgen, Pain, Pediatrics, DLQI, Skin, Nausea, Vomiting, Queen's University, AMGN, AAD, Safety, University, FRCPC, University of Alberta, PASI, Dermatology Life Quality Index, Patient, PST, Scalp, Ageing, Abdominal pain, Poster, American Academy, Pharmaceutical industry

THOUSAND OAKS, Calif., March 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new, 52-week results from the Phase 3 SPROUT study examining the use of Otezla® (apremilast) in children and adolescents aged 6 to 17 years with moderate to severe plaque psoriasis. These data, along with findings from a Phase 3 late-breaking study on Otezla in palmoplantar pustulosis, will be presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting, March 8-12 in San Diego.                                     

Key Points: 
  • These data, along with findings from a Phase 3 late-breaking study on Otezla in palmoplantar pustulosis, will be presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting, March 8-12 in San Diego.
  • "These data reflect Amgen's commitment to exploring new ways to treat inflammatory skin disease," said Ponda Motsepe-Ditshego, vice president, Global Medical, at Amgen.
  • Continued Otezla use resulted in sustained improvements in psoriasis severity and skin involvement in patients for up to one year.
  • Findings will be presented as a late-breaking oral presentation on Saturday, March 9 at 9:20 a.m. PST.

Bob Azelby to join Cardinal Health Board of Directors

Retrieved on: 
Wednesday, February 28, 2024
Amgen, Cardinal Health, MBA, ADC, Juno Therapeutics, University, Therapy, Organization, CAH, Harvard Business School, Religious studies, Clovis Oncology, Lundbeck Seattle Biopharmaceuticals, Management

DUBLIN, Ohio, Feb. 28, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors has elected Robert "Bob" Azelby as an independent director, effective March 1.

Key Points: 
  • DUBLIN, Ohio, Feb. 28, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors has elected Robert "Bob" Azelby as an independent director, effective March 1.
  • Mr. Azelby joins the board with over 30 years of experience, including as a Chief Executive Officer and board member for large, matrixed organizations in the biopharmaceutical, oncology and other specialty industries.
  • Mr. Azelby currently serves on the Boards of Directors of ADC Therapeutics and Autolus Therapeutics.
  • "Bob Azelby is a highly respected healthcare industry leader with a strong track record of leading large, complex organizations as both a CEO and a board member," said Greg Kenny, Chairman of the Board for Cardinal Health.

AMGEN OPENS STATE-OF-THE-ART BIOMANUFACTURING SITE IN CENTRAL OHIO

Retrieved on: 
Monday, February 26, 2024
Amgen, AMGN, Disease, Made, Columbus State Community College, Carbon, Partnership

"Our new facility, known as Amgen Ohio, was designed with the latest innovation and technology to deliver safe, reliable medicines for 'every patient, every time,'" said Robert A. Bradway, chairman and chief executive officer at Amgen.

Key Points: 
  • "Our new facility, known as Amgen Ohio, was designed with the latest innovation and technology to deliver safe, reliable medicines for 'every patient, every time,'" said Robert A. Bradway, chairman and chief executive officer at Amgen.
  • "As part of Amgen's global biomanufacturing network, Amgen Ohio will play an important role in helping us address serious disease around the world with our innovative biomedicines."
  • "Winning this project for Ohio creates 400 high-paying jobs and a $40 million annual payroll, supporting families and further growing the Ohio economy."
  • In partnership with Columbus State Community College, Amgen is hosting an inaugural 18-month manufacturing apprenticeship at the site.

Global Nanomedicine Market Report 2023-2028: United States Emerges as a Key Player

Retrieved on: 
Monday, February 26, 2024
Therapy, Incidence, Natural language processing, Merck, Regenerative medicine, Laboratory, Infection, Gilead Sciences, Nanostructure, Dendrimer, Chronic condition, Investment, Nanocarriers, Quality of life, Ageing, Growth, Johnson & Johnson, Conditional sentence, Government, World Health Organization, Urbanization, Nanotechnology, Geography, Prevalence, Safety, Nanoparticle, Attention, Administration, GE HealthCare, Liposome, Nanomaterials, Abbott Laboratories, Organization, Medicine, Notifiable disease, Diagnosis, Machine learning, Deep learning, Amgen, Research, Cancer

DUBLIN, Feb. 26, 2024 /PRNewswire/ -- The "Nanomedicine Market - Forecasts from 2023 to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 26, 2024 /PRNewswire/ -- The "Nanomedicine Market - Forecasts from 2023 to 2028" report has been added to ResearchAndMarkets.com's offering.
  • The nanomedicine market size is still developing, with ongoing research and development aimed at increasing nanomedicine products' efficacy, safety, and scalability.
  • Due to significant investments made by research facilities, pharmaceutical companies, and the government, the United States has a sizable nanomedicine market revenue share.
  • Key Players in the Nanomedicine Market:
    Abbott Laboratories: Nanomaterials, diagnostics, and medical equipment are the primary areas of focus at Abbott Laboratories.

Black Health Matters Winter Health Summit and Expo Returns to Atlanta

Retrieved on: 
Wednesday, February 21, 2024
HCS, Blood pressure, Chronic kidney disease, Merck, Expo, Doctor of Philosophy, BHM, Anemia, Courage, Professor, Lunch, Conditional sentence, Amgen, Cholesterol, Blood, Obesity, DD, Conference, Health, Boehringer Ingelheim, STD, Maternal health, BMI, Lilly, JD, Radio, PSA, WAOK, Guru, Health equity, FREE, Interior design

NEW YORK, Feb. 21, 2024 /PRNewswire/ -- Following an incredibly successful inaugural event in 2023, Black Health Matters (BHM) is once more bringing its celebrated health summit series to Atlanta. On Saturday, March 2nd, 2024, the Black Health Matters Winter Health Summit & Expo will be held at the downtown Atlanta Loudermilk Conference Center, 40 Courtland St. N.E., from 8:30 AM to 4:00 PM EST. This FREE, hybrid (in-person and virtual) event will offer attendees a singular wellness experience, connecting dynamic experts on chronic illness and healthiness, patient advocates and celebrity guests with the public. Those who attend will benefit from free health screenings and immunizations, presentations on chronic disease management, invigorating fitness sessions, entertainment and more. Complimentary breakfast, lunch and parking will be offered, along with FREE giveaways and prizes. To register go to www.bhm2024wintersummit.com for in-person or virtual attendance.

Key Points: 
  • Theme is "Inspiration for Your Mind, Body and Soul"
    NEW YORK, Feb. 21, 2024 /PRNewswire/ -- Following an incredibly successful inaugural event in 2023, Black Health Matters (BHM) is once more bringing its celebrated health summit series to Atlanta.
  • On Saturday, March 2nd, 2024, the Black Health Matters Winter Health Summit & Expo will be held at the downtown Atlanta Loudermilk Conference Center, 40 Courtland St.
  • "The Winter Health Summit and Expo can be your ally on your path to better health and wellness," says Roslyn Young Daniels, founder, and president of Black Health Matters.
  • The Black Health Matters Winter Summit & Expo's impressive list of sponsors includes Amgen, Boehringer Ingelheim, Johnson & Johnson HCS Advocacy, Johnson & Johnson Innovative Medicine Clinical Trials, Lilly, Merck, Pfizer, and Vertex.

Smart Immune appoints key new members to its Board of Directors

Retrieved on: 
Friday, February 16, 2024
Transfer, Research, Infection, Growth, National Cancer Institute, Immunology, Treatment, Gesellschaft mit beschränkter Haftung, Therapy, Chemical industry in India, Development, Immune system, Roche, Amgen, Dow Chemical Company, Novartis, Farmitalia, Dow, Lazard, XPath, Medical research, Spark Therapeutics, ADC, Patient, Sanofi

Markus Goebel, Grégoire Cayatte, Federico Mingozzi and Pablo Silveri will join existing directors, Dominique Costantini and Fouzia Laghrissi-Thode, to accelerate and support the growth of Smart Immune.

Key Points: 
  • Markus Goebel, Grégoire Cayatte, Federico Mingozzi and Pablo Silveri will join existing directors, Dominique Costantini and Fouzia Laghrissi-Thode, to accelerate and support the growth of Smart Immune.
  • Karine Rossignol, CEO and Co-founder of Smart Immune, said: “We are delighted and proud to welcome such distinguished experts to the Board, led by Markus Goebel as our new Chairman.
  • We are grateful to our outgoing Chairman for his 5-year commitment and support to Smart Immune.”
    Markus Goebel, CEO and Founder of M&G Advisors and Chairman of Smart Immune’s Board of Directors, said: “I am thrilled to join and lead the Board of Smart Immune.
  • He is on the Boards of Halozyme, ADC Therapeutics and Aprea Therapeutics and now an Observer on the Board of Directors at Smart Immune.

NBC10's Latoyia Edwards to Host NSBE Boston's 6th Annual Inspire STEM Gala

Retrieved on: 
Thursday, February 15, 2024
Port, Research, Senior lecturer, Boston (magazine), STEM, Amgen, MIT, Sarepta Therapeutics, Achievement Medal, Randolph, Massachusetts, Therapy, Associate, National Society, Olin College, Black history, NSBE, Student, Nightclub

With the theme "Black is STEM," this year's gala recognizes Black History in the making.

Key Points: 
  • With the theme "Black is STEM," this year's gala recognizes Black History in the making.
  • Hosted by Emmy-award winning news anchor Latoyia Edwards , the gala promises an evening of inspiration and recognition.
  • The 6th Annual Inspire STEM Gala will take place from 7:00 pm to 9:30 pm on February 24th.
  • Join NBC10's Latoyia Edwards, NSBE Boston, and keynote speaker Janeen Uzzell for a night of Black STEM excellence.

Scholar Rock Announces the Addition of Katie Peng to Its Board of Directors and Promotes Mo Qatanani, Ph.D. to Chief Scientific Officer

Retrieved on: 
Thursday, February 15, 2024
Oncology, Health, Neurology, Genetics, Pharmaceutical, Cardiology, Biotechnology, Alexion Pharmaceuticals, Ophthalmology, Indiana University, Metabolism, Rock, Growth, Diabetes, MBA, Allergan, Doctor of Philosophy, SMA, Genentech, Roche, University, Therapy, MPH, Medicine, American University, Baylor College of Medicine, Gongshi, Master of Science, Obesity, Research, Spinal muscular atrophy, Amgen, Management

“We are pleased to welcome Katie to Scholar Rock’s Board of Directors at a pivotal time when the company is preparing for the potential launch of apitegromab next year,” said David Hallal, Chairman of the Board of Scholar Rock.

Key Points: 
  • “We are pleased to welcome Katie to Scholar Rock’s Board of Directors at a pivotal time when the company is preparing for the potential launch of apitegromab next year,” said David Hallal, Chairman of the Board of Scholar Rock.
  • Katie joining our Board reflects the continued evolution of Scholar Rock, and as part of this process, Amir Nashat will be stepping down from the Board at this year’s annual shareholder meeting.
  • Prior to joining Denali, Ms. Peng managed a neurology, ophthalmology, immunology, and rare disease portfolio representing approximately $14 billion in revenue at Genentech.
  • “I am thrilled to join Scholar Rock’s Board of Directors as the company prepares for its first potential commercial launch of apitegromab.